SAB Biotherapeutics, Inc. (SABS) Share-based Payment Arrangement, Expense USD 2021 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
SAB Biotherapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2021 to 2024.
  • SAB Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $617 K, a 2.43% increase year-over-year.
  • SAB Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $2.44 M, a 2.48% increase year-over-year.
  • SAB Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2.42 M, a 9.37% decline from 2022.
  • SAB Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2.67 M, a 15.5% increase from 2021.
  • SAB Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $2.31 M, a 78.7% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $2.44 M $617 K +$14.7 K +2.43% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-20
Q4 2023 $2.42 M $537 K -$91.7 K -14.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-29
Q3 2023 $2.52 M $639 K +$61 K +10.6% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $2.45 M $645 K +$75 K +13.2% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-21
Q1 2023 $2.38 M $603 K -$295 K -32.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-20
Q4 2022 $2.67 M $629 K -$22.9 K -3.52% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 $2.7 M $578 K -$302 K -34.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $3 M $570 K +$136 K +31.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-21
Q1 2022 $2.86 M $898 K +$548 K +157% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $2.31 M $651 K Oct 1, 2021 Dec 31, 2021 10-K/A 2023-04-28
Q3 2021 $881 K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $433 K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $349 K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.